JP2019513799A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513799A5 JP2019513799A5 JP2018554487A JP2018554487A JP2019513799A5 JP 2019513799 A5 JP2019513799 A5 JP 2019513799A5 JP 2018554487 A JP2018554487 A JP 2018554487A JP 2018554487 A JP2018554487 A JP 2018554487A JP 2019513799 A5 JP2019513799 A5 JP 2019513799A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- fragment
- active ingredient
- extracellular matrix
- matrix component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 11
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 9
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 9
- 210000002744 extracellular matrix Anatomy 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 9
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims 2
- 108030001720 Bontoxilysin Proteins 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- 102000016942 Elastin Human genes 0.000 claims 2
- 108010014258 Elastin Proteins 0.000 claims 2
- 102000016359 Fibronectins Human genes 0.000 claims 2
- 108010067306 Fibronectins Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000004856 Lectins Human genes 0.000 claims 2
- 108090001090 Lectins Proteins 0.000 claims 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 2
- 230000003444 anaesthetic effect Effects 0.000 claims 2
- 230000000202 analgesic effect Effects 0.000 claims 2
- 230000000844 anti-bacterial effect Effects 0.000 claims 2
- 230000000843 anti-fungal effect Effects 0.000 claims 2
- 229940121375 antifungal agent Drugs 0.000 claims 2
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims 2
- 229960002470 bimatoprost Drugs 0.000 claims 2
- 229940053031 botulinum toxin Drugs 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 229930182912 cyclosporin Natural products 0.000 claims 2
- 229920002549 elastin Polymers 0.000 claims 2
- 229960002870 gabapentin Drugs 0.000 claims 2
- 229920002674 hyaluronan Polymers 0.000 claims 2
- 229960003160 hyaluronic acid Drugs 0.000 claims 2
- 229960000890 hydrocortisone Drugs 0.000 claims 2
- 239000002523 lectin Substances 0.000 claims 2
- 229960004194 lidocaine Drugs 0.000 claims 2
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 claims 2
- 229960004023 minocycline Drugs 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229960001233 pregabalin Drugs 0.000 claims 2
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims 2
- 229960003471 retinol Drugs 0.000 claims 2
- 235000020944 retinol Nutrition 0.000 claims 2
- 239000011607 retinol Substances 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims 2
- 229960001860 salicylate Drugs 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims 2
- 229960000835 tadalafil Drugs 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 239000003906 humectant Substances 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 239000004014 plasticizer Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 239000000080 wetting agent Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662321626P | 2016-04-12 | 2016-04-12 | |
| US62/321,626 | 2016-04-12 | ||
| PCT/US2017/027275 WO2017180788A1 (en) | 2016-04-12 | 2017-04-12 | Compositions for topical application of compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019513799A JP2019513799A (ja) | 2019-05-30 |
| JP2019513799A5 true JP2019513799A5 (enExample) | 2020-01-09 |
Family
ID=59999163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554487A Pending JP2019513799A (ja) | 2016-04-12 | 2017-04-12 | 化合物の局所適用を目的とした組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20170290778A1 (enExample) |
| EP (1) | EP3442488A4 (enExample) |
| JP (1) | JP2019513799A (enExample) |
| KR (1) | KR20190022476A (enExample) |
| CN (1) | CN109152702A (enExample) |
| AU (1) | AU2017250267A1 (enExample) |
| CA (1) | CA3020400A1 (enExample) |
| IL (1) | IL262180B2 (enExample) |
| MX (1) | MX2018012486A (enExample) |
| SG (1) | SG11201808990QA (enExample) |
| WO (1) | WO2017180788A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
| KR20070110402A (ko) * | 2005-03-03 | 2007-11-16 | 레반스 테라퓨틱스 | 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및방법 |
| US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
| CN102869373B (zh) | 2009-06-25 | 2017-05-10 | 雷文斯治疗公司 | 不含白蛋白的肉毒杆菌毒素制剂 |
| WO2011013009A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
| AU2010302350B2 (en) | 2009-10-02 | 2015-06-18 | Journey Medical Corporation | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
| US12661407B2 (en) | 2010-04-08 | 2026-06-23 | Journey Medical Corporation | Compositions, gels and foams with rheology modulators and uses thereof |
| MX2020012139A (es) | 2016-09-08 | 2021-01-29 | Vyne Pharmaceuticals Inc | Composiciones y metodos para tratar rosacea y acne. |
| JP7217700B2 (ja) | 2016-09-13 | 2023-02-03 | アラーガン、インコーポレイテッド | 安定化非タンパク質クロストリジウム毒素組成物 |
| US11040090B2 (en) * | 2016-12-08 | 2021-06-22 | Prime Bio, Inc | Botulinum neurotoxin compositions |
| CA3078631A1 (en) * | 2017-10-11 | 2019-04-18 | Jacob M. Waugh | Methods and compositions for topical delivery |
| CN119157876A (zh) | 2017-12-15 | 2024-12-20 | 塔苏斯制药有限公司 | 用于治疗睑炎的异恶唑啉驱虫剂制剂和方法 |
| KR102189632B1 (ko) * | 2018-03-09 | 2020-12-11 | 전남대학교산학협력단 | 신규 균주 페니실리움 애시둠 및 이의 용도 |
| KR101899413B1 (ko) * | 2018-05-03 | 2018-09-18 | 주식회사 케어사이드 | 피부 감염의 예방 또는 치료용 조성물 |
| WO2020004234A1 (ja) | 2018-06-26 | 2020-01-02 | 久光製薬株式会社 | マイクロニードルデバイス及びそれを製造する方法 |
| KR102088104B1 (ko) * | 2018-06-29 | 2020-03-11 | 호서대학교 산학협력단 | 개망초 꽃 에센셜 오일을 포함하는 신경 근육 관련 질환 예방 및 치료용 조성물 |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| US12502377B2 (en) | 2019-04-04 | 2025-12-23 | Tarsus Pharmaceuticals, Inc. | Method of eradicating ticks that attach to humans using lotilaner formulations |
| CN111825775B (zh) * | 2019-04-18 | 2021-11-02 | 复旦大学 | 密枝圆柏多糖及其制备方法和在制备抗肿瘤药物中的用途 |
| CN110090193B (zh) * | 2019-05-14 | 2022-04-12 | 东方爱堡(北京)母婴健康科技有限公司 | 一种具有减脂功效的祛痘保湿精华液及其制备方法 |
| US20210000910A1 (en) | 2019-07-03 | 2021-01-07 | Jysk Skin Solutions Pte Ltd | Topical compositions |
| EP4081540A4 (en) * | 2019-12-24 | 2024-01-31 | Dyve Biosciences, Inc. | TOPICAL CYCLOSPORINE FOR THE TREATMENT OF PSORIASIS AND OTHER DISEASES |
| CN111281980B (zh) * | 2020-02-05 | 2025-01-24 | 芽米科技(广州)有限公司 | 一种水溶性γ-聚谷氨酸-替米考星复合物及其制备方法 |
| CN111110831B (zh) * | 2020-02-20 | 2023-08-08 | 柳州市工人医院 | 一种溃疡糊剂及其制备方法 |
| CN111297884B (zh) * | 2020-04-02 | 2021-03-30 | 中国农业科学院蜜蜂研究所 | 腺苷在蜜蜂病毒感染防治中的应用 |
| CN111329846A (zh) * | 2020-04-24 | 2020-06-26 | 云南伦扬科技有限公司 | 一种阴道杀菌贴膜及其制备方法 |
| CN111587861A (zh) * | 2020-05-21 | 2020-08-28 | 广州市穗升有害生物防治中心 | 引诱箱 |
| KR20240127867A (ko) * | 2020-08-10 | 2024-08-23 | 지로파, 인코포레이티드 | 국소 전달을 위한 조성물 및 방법 |
| KR20240125432A (ko) * | 2020-09-29 | 2024-08-19 | 지로파, 인코포레이티드 | 통증 완화 및 마취를 위한 조성물 및 방법 |
| JP2023546445A (ja) * | 2020-10-22 | 2023-11-02 | ファイザー・インク | コルチコステロイドの非経口投与のためのｐｅｇフリー水性懸濁液 |
| CN114617974B (zh) * | 2020-12-10 | 2023-10-03 | 中国科学院苏州纳米技术与纳米仿生研究所 | 一种多肽白蛋白纳米粒及其制备方法和应用 |
| HU231397B1 (hu) | 2021-01-22 | 2023-06-28 | Egis Gyógyszergyár Zrt. | Pregabalint tartalmazó topikális gyógyszerkészítmény |
| MX2023008647A (es) | 2021-01-22 | 2023-08-01 | Egyt Gyogyszervegyeszeti Gyar | Formulacion topica que contiene pregabalina dispersada. |
| JP2024506865A (ja) * | 2021-02-05 | 2024-02-15 | モダン メドウ，インコーポレイテッド | スキンケア組成物及びその使用方法 |
| WO2022232161A1 (en) * | 2021-04-26 | 2022-11-03 | Sypherion, Llc | Inhibitors of nsp1 for treatment of sars-cov-2 |
| CN113332238A (zh) * | 2021-06-09 | 2021-09-03 | 四川恒通动保生物科技有限公司 | 一种加米霉素的复合溶液剂的制备方法 |
| JP7141025B1 (ja) * | 2021-11-11 | 2022-09-22 | エルデシエロ プライベート リミテッド | 化合物、組成物、方法、及び製造方法 |
| WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
| CN117088938A (zh) * | 2022-05-13 | 2023-11-21 | 四川省中医药科学院 | 一种对抗细胞因子风暴或细胞因子释放综合征的麝香提取物及其制备方法和应用 |
| CN117186177B (zh) * | 2022-05-31 | 2024-08-23 | 中国农业大学 | 一种具有降尿酸活性的鸭血球蛋白肽及其制备方法 |
| US12083204B2 (en) | 2022-06-02 | 2024-09-10 | L'oreal | Topical composition for homeostatic delivery of nitric oxide and uses thereof |
| WO2024007014A2 (en) * | 2022-06-30 | 2024-01-04 | Board Of Trustees Of The University Of Arkansas | Process for treating livestock exposed to toxic forage using melatonin compositions |
| CN117582442A (zh) * | 2022-08-18 | 2024-02-23 | 智泽童康(广州)生物科技有限公司 | 双嘧达莫在制备防治蚊虫叮咬的产品中的应用 |
| AU2023352919A1 (en) | 2022-09-29 | 2025-03-13 | Adora Life Science, Inc. | Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions |
| CN116098882A (zh) * | 2023-04-06 | 2023-05-12 | 山东诚创蓝海医药科技有限公司 | 一种含利多卡因丙胺卡因的组合物及其制备方法 |
| CN116791274B (zh) * | 2023-06-16 | 2026-03-27 | 福建恒安集团有限公司 | 一种超柔软爽滑纯棉无纺布的制备方法及其应用 |
| CN116870001B (zh) * | 2023-08-11 | 2024-08-27 | 云南中医药大学 | 吲哚-3-甲酸衍生物与氟康唑联合在制备抗耐药白念珠菌药物中的应用 |
| CN117838583B (zh) * | 2023-09-28 | 2026-08-11 | 山东福瑞达生物股份有限公司 | 一种抗光老化护肤组合物及其制备方法和应用 |
| CN117427027B (zh) * | 2023-12-21 | 2024-04-23 | 舒芙雅生物科技有限公司 | 一种祛痘组合物及其制备方法 |
| US12357725B1 (en) | 2024-05-30 | 2025-07-15 | King Saud University | Clinical dressing loaded with coffee extract |
| CN120284984B (zh) * | 2025-04-25 | 2025-10-17 | 首都医科大学附属北京胸科医院 | 一种抗结核分枝杆菌感染的化合物及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5234914A (en) * | 1991-06-11 | 1993-08-10 | Patent Biopharmaceutics, Inc. | Methods of treating hemorrhoids and anorecial disease |
| IT1260148B (it) * | 1992-04-17 | 1996-03-28 | Fidia Spa | Impiego di preparazioni di acido ialuronico per la formazione di tessuto osseo |
| US8728510B1 (en) * | 2002-03-15 | 2014-05-20 | Advanced Cardiovascular Systems, Inc. | Biocompatible carrier containing a bioadhesive material |
| US7956180B2 (en) * | 2004-05-27 | 2011-06-07 | Novozymes A/S | Dried and agglomerated hyaluronic acid product |
| WO2006063021A2 (en) * | 2004-12-07 | 2006-06-15 | Surmodics, Inc. | Coatngs with crystallized active agents (s) |
| US7727537B2 (en) * | 2005-02-14 | 2010-06-01 | Dpm Therapeutics Corp. | Stabilized compositions for topical administration and methods of making same |
| ES2747978T3 (es) * | 2005-10-03 | 2020-03-12 | Mark A Pinsky | Liposomas no fosfolipídicos que comprenden ácido hialurónico |
| AU2006352358B2 (en) * | 2006-12-26 | 2014-03-13 | Bomi Patel Framroze | Skin lightening composition for hyperpigmented skin |
| US20100272697A1 (en) * | 2007-04-10 | 2010-10-28 | Ali Naji | Pancreatic islet cells composition and methods |
| JP5261680B2 (ja) * | 2007-08-09 | 2013-08-14 | キッコーマンバイオケミファ株式会社 | ヒアルロン酸プロピレングリコールエステルおよびそれを用いた皮膚外用剤 |
| DE102008034265A1 (de) * | 2008-07-22 | 2010-01-28 | Beiersdorf Ag | Wirkstoffkombination aus Anisfruchtextrakt und Hyaluronsäure |
| KR101610985B1 (ko) * | 2008-11-14 | 2016-04-08 | 히스토젠, 인코포레이티드 | 암 치료를 위한 세포외 기질 조성물 |
| US8679470B2 (en) * | 2008-11-28 | 2014-03-25 | Luromed Llc | Composition using cross-linked hyaluronic acid for topical cosmetic and therapeutic applications |
| EP3205344A1 (en) * | 2009-05-19 | 2017-08-16 | Plurogen Therapeutics, LLC | Surface active agent compositions and methods for enhancing oxygenation, reducing bacteria and improving wound healing |
| CA2762212C (en) * | 2009-05-20 | 2015-12-29 | Humacyte, Inc. | Elastin for soft tissue augmentation |
| CA2703532C (en) * | 2010-05-10 | 2018-05-01 | Eva Turley | Topically administered, skin-penetrating glycosaminoglycan formulations suitable for use in cosmetic and pharmaceutical applications |
| US20110305737A1 (en) * | 2010-06-09 | 2011-12-15 | NY Derm LLC | Multi-Active Microtargeted Anti-Aging Skin Cream Polymer Technology |
| FR2971711B1 (fr) * | 2011-02-18 | 2014-06-13 | Isp Investments Inc | Composition cosmetique comprenant un extrait de petit epeautre en tant qu'agent activateur de la synthese des proteines de la matrice extracellulaire |
| WO2014134532A1 (en) * | 2013-02-28 | 2014-09-04 | Ventrix, Inc. | Methods and compositions for tissue therapy and analysis |
| EP2961945B1 (en) * | 2013-02-28 | 2020-09-02 | United Technologies Corporation | Method and apparatus for collecting pre-diffuser airflow and routing it to combustor pre-swirlers |
| US10111801B2 (en) * | 2013-03-05 | 2018-10-30 | Dante Liberatoscioli | Apparatus for relieving back pain |
-
2017
- 2017-04-12 CA CA3020400A patent/CA3020400A1/en not_active Abandoned
- 2017-04-12 WO PCT/US2017/027275 patent/WO2017180788A1/en not_active Ceased
- 2017-04-12 AU AU2017250267A patent/AU2017250267A1/en not_active Abandoned
- 2017-04-12 EP EP17783085.8A patent/EP3442488A4/en not_active Withdrawn
- 2017-04-12 KR KR1020187032806A patent/KR20190022476A/ko not_active Ceased
- 2017-04-12 JP JP2018554487A patent/JP2019513799A/ja active Pending
- 2017-04-12 IL IL262180A patent/IL262180B2/en unknown
- 2017-04-12 MX MX2018012486A patent/MX2018012486A/es unknown
- 2017-04-12 SG SG11201808990QA patent/SG11201808990QA/en unknown
- 2017-04-12 CN CN201780025623.6A patent/CN109152702A/zh active Pending
- 2017-04-12 US US15/486,240 patent/US20170290778A1/en not_active Abandoned
-
2018
- 2018-09-14 US US16/131,859 patent/US20190008795A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12403091B2 (en) | Delivery system | |
| US10085994B2 (en) | Topical compositions and methods of treatment of topical disorders | |
| JP5401457B2 (ja) | 抗菌ペプチド、組成物及びその使用方法 | |
| US10179159B2 (en) | Topical anesthetic formulation | |
| US9642895B2 (en) | Peptides for enhancing transdermal delivery | |
| AU2013289403B2 (en) | Diclofenac formulations | |
| JP2016527188A5 (enExample) | ||
| KR20190022476A (ko) | 화합물의 국소 도포용 조성물 | |
| EA200901112A1 (ru) | Жидкие композиции, образующие дермальные пленки, для введения лекарственных препаратов в кожу | |
| EP3177286A1 (en) | Compositions and methods for physiological delivery using cannabidiol | |
| Aronson | Antifungal drugs |